IDIBELL licenses Histocell, a patent for acute respiratory diseases with stem cells

Public release date: 27-Mar-2013 [ | E-mail | Share ]

Contact: Jordi Morato comunicacio@idibell.cat IDIBELL-Bellvitge Biomedical Research Institute

The Bellvitge Biomedical Research Institute (IDIBELL) has signed a licensing agreement with the Spanish biotech company Histocell to make use of a patent for the treatment of acute pulmonary diseases with mesenchymal stem cells. These cells, administered intravenously, have the ability to go directly to the damaged lungs, acting as a "smart drug".

To enhance the effect, researchers have modified this cells by genetic engineering. The studies have been developed by a team led by Josep Maria Aran, researcher at the Human Molecular Genetics group of IDIBELL, in collaboration with researchers of the Pneumology group at Vall d'Hebron Research Institute (VHIR) and the Biomedical Research Network Centre for Respiratory Diseases (CIBERES). The outcomes of the research have supposed an international patent application managed by the Technology Transfer Office (TTO) at IDIBELL.

The researchers use adult mesenchymal stem cells extracted from adipose tissue obtained from liposuction. These cells are capable of enhancing the regeneration of the damaged lung tissue and secrete inflammatory proteins therein when injected into the blood.

Improvements

The novelty patented by IDIBELL and VHIR researchers has been the insertion of improvements through genetic engineering that can significantly enhance the anti-inflammatory and regenerative power of the mesenchymal cells. Specifically, researchers have modified the antagonist to secrete interleukin 33, a regulatory protein (cytokine) that has a fundamental role in the inflammatory process.

The treatment has proven to be very effective given intravenously, although it could be considered the option of administering it by inhalation.

In the administered dose, these stem cells do not involve immune rejection, because the body removes them after their function is performed. This makes them particularly useful for treating acute diseases.

Good results

See more here:
IDIBELL licenses Histocell, a patent for acute respiratory diseases with stem cells